Medtronic Stock Price, News & Analysis

A new Medtronic survey reveals concerning gaps in women's heart health awareness. Despite cardiovascular disease being the #1 killer of women in the U.S., 56% of women have never discussed heart health with their mothers or family members. The survey found that 45% of women were more likely to discuss sensitive topics like politics or money before family heart health history. Notably, 94% of women are responsible for family health decisions, yet 60% struggle to prioritize their own health. Women face significant disparities in heart disease treatment, being 35% less likely to receive minimally invasive solutions for heart valve failure compared to men. The impact is particularly severe among women of color, with 43% of Hispanic women and 59% of Black women experiencing cardiovascular disease. In response, Medtronic launched the 'Letter to My Mother' campaign to encourage heart health conversations and awareness.

Medtronic (NYSE: MDT) announced positive clinical outcomes from two studies using their Affera™ family of technologies for atrial fibrillation treatment. The Sphere-360™ single-shot PFA catheter demonstrated 88% freedom from arrhythmia recurrence and 98% pulmonary vein isolation at one year, with no reported safety events in the optimized waveform group.

The Sphere-9™ catheter showed effectiveness for linear ablation in persistent AFib patients, based on sub-analysis from the Sphere Per-AF IDE study. The device received FDA approval in October 2024. Medtronic plans to begin U.S. pivotal trials for Sphere-360 later this year.

The company currently offers two PFA solutions: the PulseSelect™ system available in over 30 countries, and the Affera system with Sphere-9 catheter available in Europe, Australia, and New Zealand. AFib affects more than 60 million people worldwide and is a progressive disease that increases risks of heart failure, stroke, and death.

Medtronic (NYSE: MDT) announced successful results from its Expand URO clinical trial for the Hugo™ robotic-assisted surgery (RAS) system. The study, the largest multi-center prospective Investigational Device Exemption (IDE) trial for multi-port robotic-assisted urologic surgery in the U.S., met both primary safety and effectiveness endpoints.

The trial included 137 patients undergoing urologic procedures. The American Urologic Association (AUA) described it as a 'practice-changing, paradigm-shifting (P2) clinical trial in urology'. Results were presented at the AUA annual meeting in Las Vegas by Dr. Michael R. Abern from Duke University Hospital, the study's national principal investigator.

Medtronic (NYSE: MDT) has received FDA approval for its OmniaSecure™ defibrillation lead, the world's smallest defibrillation lead at 4.7 French (1.6mm). The device is approved for right ventricle placement in adults and pediatric patients aged 12 and up.

The lead, built on the SelectSecure™ Model 3830 pacing lead platform, connects to implantable defibrillators to treat life-threatening heart rhythm conditions. The company also presented investigational study results at Heart Rhythm 2025, showing 100% defibrillation success when the lead is implanted in the left bundle branch (LBB) area.

The LEADR LBBAP clinical study demonstrated a 95.8% successful implantation rate in the first 193 patients, with no procedure-related major complications. The study enrolled approximately 300 patients across 24 sites in 11 countries. The smaller diameter aims to reduce complications such as venous occlusion and tricuspid valve regurgitation.

Medtronic (NYSE: MDT) has submitted 510(k) applications to the FDA for clearance of an interoperable insulin pump system that would integrate with Abbott's advanced CGM platform. The submission includes the MiniMed™ 780G pump as an alternate controller enabled (ACE) insulin pump and the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC).

This development follows last August's collaboration announcement between Medtronic and Abbott. Under the partnership, Abbott will provide Medtronic with CGM technology that will work exclusively with Medtronic's smart dosing devices and software for both automated insulin delivery and smart multiple daily injections systems. These integrated systems will be marketed solely by Medtronic.

Medtronic (NYSE: MDT) has received FDA approval for its Simplera Sync™ sensor for use with the MiniMed™ 780G system. The new disposable, all-in-one sensor requires no fingersticks with SmartGuard™ and features a simplified two-step insertion process.

The MiniMed™ 780G system's adaptive algorithm automatically adjusts glucose levels every 5 minutes using Meal Detection™ technology. Real-world data shows users achieve time in range above 70% when using optimal settings. The system works with the world's only 7-day infusion set, reducing injections by 96% compared to daily injections.

A launch of the Simplera Sync™ sensor in the U.S. is scheduled for fall 2025. Currently, the MiniMed™ 780G system operates with the Guardian™ 4 sensor.

Medtronic (NYSE: MDT) has announced compelling five-year outcomes from the Evolut Low Risk Trial for its Evolut™ TAVR system. The study, involving 1,414 patients (730 TAVR, 684 surgery), demonstrated that TAVR patients experienced comparable rates of all-cause mortality or disabling stroke (15.5%) versus surgery (16.4%) at five years.

Key findings showed a numerically lower rate of cardiovascular mortality in TAVR patients (7.2%) compared to surgery (9.3%), along with significantly larger effective orifice areas and lower mean gradients. The trial evaluated patients with severe aortic stenosis who had a predicted 30-day mortality risk below 3%.

The results, presented at the American College of Cardiology's Annual Scientific Session & Expo, support Evolut's supra-annular, self-expanding TAVR as a durable and effective alternative to surgery for severe aortic stenosis patients, regardless of surgical risk.

Medtronic (NYSE: MDT) has released two-year results from the SMART Trial, comparing their Evolut TAVR system with SAPIEN TAVR in patients with small aortic annulus. The study, presented at CRT 2025, is the largest international head-to-head comparative trial primarily enrolling women (87% of 716 patients) across 80+ sites worldwide.

The trial demonstrated comparable outcomes in mortality, disabling stroke, and heart failure hospitalization between both devices. However, Evolut TAVR showed superior valve performance with significantly less bioprosthetic valve dysfunction (BVD). Key findings include five times less prosthetic valve thrombosis and nine times less hemodynamic structural valve dysfunction compared to SAPIEN TAVR.

Medtronic (NYSE: MDT) has declared a quarterly cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025. The dividend will be paid on April 11, 2025, to shareholders of record as of March 28, 2025.

This declaration aligns with the dividend increase announced in May 2024. As a member of the S&P 500 Dividend Aristocrats index, Medtronic has maintained a 47-year streak of consecutive annual dividend increases.

Headquartered in Galway, Ireland, Medtronic is a global healthcare technology company with 95,000+ employees across more than 150 countries. The company develops technologies and therapies for 70 health conditions, including cardiac devices, surgical robotics, insulin pumps, surgical tools, and patient monitoring systems.